InMed Files Provisional Patent

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.

As quoted in the press release:

The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.

This will be the first in a series of patent applications directed to various aspects of the Company’s biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data.  The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course.

Click here to read the full press release.

Get the Latest Cannabis Investing Stock Information

Get the latest information about companies associated with Cannabis Investing delivered directly to your inbox.

Cannabis

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply